Igenica Lands $14,000,000 Series C Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c0f3c9f5-df4a-4e38-bbaa-eee5a7e20440 - Date
1/28/2014 - Company Name
Igenica - Mailing Address
863 Mitten Road Burlingame, CA 94010 - Company Description
Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. - Website
http://www.igenica.com - Transaction Type
Venture Equity - Transaction Amount
$14,000,000 - Transaction Round
Series C - Proceeds Purposes
As we strengthen our product focus, these funds will be used to advance IGN523 through early clinical trials aimed at safety and clinical activity assessments in acute myelogeneous leukemia. It also will enable us to continue to discover and develop new therapeutics based on our innovative ADC platform to expand Igenica’s pipeline and to increase strategic flexibility as we execute on our business and clinical development plans. - M&A Terms
- Venture Investor
The Column Group - Venture Investor
5AM Ventures - Venture Investor
OrbiMed Advisors - Venture Investor
Third Rock Ventures
